Endpoints News 生物医药· Lei Lei Wu·· 2026-10-14AI 评分47
Vir Biotech与Gilead达成实体瘤T细胞接合器合作,获6500万美元首付款
Vir makes solid tumor T cell engager deal with Gilead
AI 导读
Vir Biotechnology与Gilead达成一项针对实体瘤T细胞接合器的合作,Gilead将向Vir支付6500万美元首付款,文中提及Vir CEO Marianne De Backer近期已多次达成交易。
正文
Vir Biotechnology and its CEO Marianne De Backer have notched yet another deal, this time with Gilead.
Gilead will pay Vir $65 million upfront, with …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news